Table 1 Univariate Cox regression analysis of overall survival for all GAC patients

From: Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors

    

95% CI for HR

Covariate

Frequency

P -value

HR

Lower

Upper

Age, years

     

 Continuous

184

0.574

1.005

0.987

1.024

Gender

     

 Females (Reference)

69

 

1.000

  

 Males

115

0.140

0.708

0.447

1.120

Race

 

0.708

   

 Caucasian (Reference)

25

 

1.000

  

 Hispanic

30

0.713

0.865

0.400

1.871

 Japanese

129

0.421

0.771

0.409

1.453

Intestinal or Diffuse

     

 Intestinal (Reference)

90

 

1.000

  

 Diffuse

94

0.403

1.216

0.769

1.924

Histologic Grade

     

 Well-Moderate

61

 

1.000

  

 Poorly

123

0.007

2.197

1.246

3.872

Location

     

 AEG3 (Reference)

32

 

1.000

  

 Gastric

152

0.909

0.960

0.476

1.936

T

 

0.000

   

 T1 (Reference)

27

 

1.000

  

 T2

88

0.041

3.479

1.055

11.471

 T3

58

0.000

9.144

2.811

29.745

 T4

11

0.000

14.692

3.871

55.761

N

 

0.000

   

 N0 (Reference)

61

 

1.000

  

 N1

72

0.007

2.596

1.304

5.167

 N2

26

0.000

5.350

2.522

11.352

 N3

25

0.000

5.583

2.522

12.362

M

     

 M0 (Reference)

151

 

1.000

  

 M1

33

0.000

4.011

2.429

6.623

Gal-3 Expression

     

 0.003.5 (Reference)

122

 

1.000

  

 1.003.5

62

0.026

1.682

1.063

2.662

  1. Abbreviations: CI=confidence interval; HR=hazard ratio.